Information om | Engelska ordet ABROCITINIB

Exempel på hur man kan använda ABROCITINIB i en mening

• The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (EMA) recommends that the Janus kinase inhibitors abrocitinib, filgotinib, baricitinib, upadacitinib, and tofacitinib should be used in the following people only if no suitable alternative treatments are available: those aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past, and those at increased risk of cancer.
• In another meta-analysis including 2256 patients from three different studies have showed that abrocitinib improved the EASI scores in comparison with dupilumab, even in the second week of treatment.

Förberedelsen av sidan tog: 77,85 ms.